Coherus BioSciences Inc (CHRS)
1.90
-0.22
(-10.38%)
USD |
NASDAQ |
May 10, 16:00
1.91
+0.01
(+0.53%)
After-Hours: 20:00
Coherus BioSciences Revenue (Quarterly): 91.52M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 91.52M |
| September 30, 2023 | 74.57M |
| June 30, 2023 | 58.72M |
| March 31, 2023 | 32.44M |
| December 31, 2022 | 45.35M |
| September 30, 2022 | 45.42M |
| June 30, 2022 | 60.15M |
| March 31, 2022 | 60.12M |
| December 31, 2021 | 73.37M |
| September 30, 2021 | 82.50M |
| June 30, 2021 | 87.64M |
| March 31, 2021 | 83.03M |
| December 31, 2020 | 110.42M |
| September 30, 2020 | 113.55M |
| June 30, 2020 | 135.67M |
| March 31, 2020 | 116.18M |
| December 31, 2019 | 123.86M |
| September 30, 2019 | 111.68M |
| June 30, 2019 | 83.43M |
| March 31, 2019 | 37.10M |
| December 31, 2018 |
| Date | Value |
|---|---|
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | 1.395M |
| March 31, 2017 | 0.161M |
| December 31, 2016 | 0.844M |
| September 30, 2016 | 162.84M |
| June 30, 2016 | 14.07M |
| March 31, 2016 | 12.36M |
| December 31, 2015 | 10.20M |
| September 30, 2015 | 7.167M |
| June 30, 2015 | 6.866M |
| March 31, 2015 | 5.81M |
| December 31, 2014 | 6.493M |
| September 30, 2014 | 16.05M |
| June 30, 2014 | 4.965M |
| March 31, 2014 | 3.596M |
| December 31, 2013 | 1.232M |
| September 30, 2013 | 0.506M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
32.44M
Minimum
Mar 2023
135.67M
Maximum
Jun 2020
83.66M
Average
83.03M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| AbbVie Inc | 12.31B |
| Inovio Pharmaceuticals Inc | 0.1027M |
| Nektar Therapeutics | 23.88M |
| Avid Bioservices Inc | 33.82M |
| Stereotaxis Inc | 4.565M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -79.65M |
| Total Expenses (Quarterly) | 160.43M |
| EPS Diluted (Quarterly) | -0.74 |
| Enterprise Value | 571.27M |
| Gross Profit Margin (Quarterly) | 7.60% |
| Profit Margin (Quarterly) | -87.03% |
| Earnings Yield | -136.8% |
| Normalized Earnings Yield | -136.84 |